NCT06762808 2025-08-15
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT04329221 2025-05-07
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Phase 2 Withdrawn
NCT04642287 2025-05-07
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Phase 2 Withdrawn
NCT04595981 2025-04-27
Chemo-embolization for Head and Neck Cancer
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT05608369 2025-04-04
HPV
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05359692 2023-09-15
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Incyte Corporation
Phase 2 Withdrawn
NCT05535023 2023-09-13
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00934518 2019-02-12
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
Milton S. Hershey Medical Center
Phase 2 Withdrawn
NCT00605709 2012-07-25
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma
BPGbio
Phase 2 Withdrawn
NCT00233636 2011-01-27
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Withdrawn